Status:
COMPLETED
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Collaborating Sponsors:
Spartan Bioscience Inc.
Conditions:
STEMI
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment elevation myocardial ...
Detailed Description
Dual anti-platelet therapy following percutaneous coronary intervention (PCI) for the treatment of STEMI has traditionally consisted of aspirin and clopidogrel. Despite this treatment approach, a subs...
Eligibility Criteria
Inclusion
- Males and Females between the ages of 18 and 75 years
- STEMI patients treated with percutaneous coronary intervention
- Able to provide informed consent
- Able to comply with assigned treatment strategy and attend 1 month follow-up visit
Exclusion
- Receiving anti-platelet therapy other than aspirin and clopidogrel
- Receiving anti-coagulation with warfarin or dabigatran
- History of stroke or transient ischemic attack
- Platelet count \< 100 000/μL
- Known Bleeding Diathesis
- Hematocrit \<30% or \>52%
- Severe Liver Dysfunction
- Renal Insufficiency (Creatinine Clearance \< 30ml/min)
- Pregnant females
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT01452139
Start Date
September 1 2011
End Date
March 1 2013
Last Update
April 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1N 4W7